Literature DB >> 9013406

Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.

T Büttner1, W Kuhn, T Müller, F L Welter, J Federlein, K Heidbrink, H Przuntek.   

Abstract

Recently distorted chromatic contour perception has been demonstrated in Parkinson's disease (PD). The aim of our study is to determine the clinical factors which influence chromatic contour perception in PD. Chromatic and achromatic contour perception, colour discrimination and clinical data were evaluated in 73 patients with PD. We used a computer-aided method to determine the chromatic fusion time (CFT) which indicates the acuity of monochromatic contour perception. Chromatic CFT was generally shortened in patients as compared to controls (p < 0.01), whereas achromatic CFT was not significantly different. Variance analysis revealed the ability of colour discrimination and the risk of visual hallucinations as statistically significant (p < 0.05) variables influencing contour perception of certain stimuli. In contrast, disease stage, disease duration and disease severity have no relevant effect on chromatic contour perception in Parkinson's disease. On the basis of those properties one may suggest that distorted chromatic contour perception is due to an impairment at a central stage of visual processing in PD and an imbalance of the serotonergic system. Whether CFT is a reliable method to predict the individual risk of hallucinosis in PD has to be evaluated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9013406     DOI: 10.1007/BF01271204

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  31 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Dopamine in the visual cortex of the cat.

Authors:  T A Reader; L F Quesney
Journal:  Experientia       Date:  1986-12-01

Review 3.  Psychiatric side effects during the treatment of Parkinson's disease.

Authors:  H L Klawans
Journal:  J Neural Transm Suppl       Date:  1988

4.  Simultaneous VEP and PERG investigations in early Parkinson's disease.

Authors:  S Calzetti; A Franchi; G Taratufolo; E Groppi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

5.  Dopaminergic innervation of the primary visual cortex in the rat, and some correlations with human cortex.

Authors:  O T Phillipson; I C Kilpatrick; M W Jones
Journal:  Brain Res Bull       Date:  1987-05       Impact factor: 4.077

6.  The colour centre in the cerebral cortex of man.

Authors:  C J Lueck; S Zeki; K J Friston; M P Deiber; P Cope; V J Cunningham; A A Lammertsma; C Kennard; R S Frackowiak
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

7.  The representation of colours in the cerebral cortex.

Authors:  S Zeki
Journal:  Nature       Date:  1980-04-03       Impact factor: 49.962

8.  Levodopa-induced psychosis: a kindling phenomenon.

Authors:  C Moskovitz; H Moses; H L Klawans
Journal:  Am J Psychiatry       Date:  1978-06       Impact factor: 18.112

9.  Color VEPs in Parkinson's disease.

Authors:  L Barbato; S Rinalduzzi; M Laurenti; S Ruggieri; N Accornero
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1994-03

10.  Distribution of catecholamines, serotonin, and their major metabolites in the rat cingulate, piriform-entorhinal, somatosensory, and visual cortex: a biochemical survey using high-performance liquid chromatography.

Authors:  T A Reader; L Grondin
Journal:  Neurochem Res       Date:  1987-12       Impact factor: 3.996

View more
  2 in total

Review 1.  Ophthalmology issues in schizophrenia.

Authors:  Carolina P B Gracitelli; Ricardo Y Abe; Alberto Diniz-Filho; Fabiana Benites Vaz-de-Lima; Augusto Paranhos; Felipe A Medeiros
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

2.  Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Authors:  Matthew J Baggott; Jennifer D Siegrist; Gantt P Galloway; Lynn C Robertson; Jeremy R Coyle; John E Mendelson
Journal:  PLoS One       Date:  2010-12-02       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.